The NEXEL is a bio-company that established in 2012 based on our own stem cell technology. Using human pluripotent stem cells (hPSCs), we are developing two main pipelines for business: 1) Developing and manufacturing the functional human cells from hPSCs for testing toxicity of new drug candidates and other research applications, 2) developing protein therapy (human stem cell-derived physiologically active protein) for acute and chronic diseases.
Regarding the human cell products, NEXEL provides the Hepatosight-S® (hPSC-derived hepatocytes), Cardiosight-S® (hPSC-derived cardiomyocytes), and Neurosight-S® (hPSC-derived neurons) as frozen vial stocks. These human cells are utilizing for the wide range of applications such as toxicity tests, drug screening, and other fields that need human hepatocytes, cardiomyocytes, and neurons. NEXEL is looking for potential distributors (sales agency) of our human cell products in overseas markets including Taiwan, Singapore, and Hongkong.
Furthermore, our protein therapy is ongoing pre-clinical study for curing liver diseases (cirrhosis, fibrosis, and NASH). This protein therapy is developed from human stem cell-derived active protein and shows powerful anti-fibrotic effect. Regarding this protein therapy, we are looking for strategic partners for co-development.